If your loved one has been using street opioids, what they've actually been putting in their body has changed significantly in the last two years. Not the fentanyl part. What's mixed in with it.
This matters because the standard detox protocol most facilities run was built for a drug supply that no longer exists in some parts of the country. Here's what changed, why it makes detox riskier than it used to be, and what to ask a facility before your loved one walks through the door.
What "Tranq" Actually Means Now
For the last several years, tranq referred to xylazine, a veterinary sedative that started showing up mixed into fentanyl. Families who did their homework learned about xylazine, learned about the wounds it causes, and learned to ask about it.
That information is already going out of date. A different veterinary sedative, medetomidine, has been rapidly replacing xylazine in the supply. In Philadelphia, medetomidine went from appearing in 29% of tested dope samples in May 2024 to 90% by March 2026, while xylazine dropped from 97% to 28%. That is close to a total flip in under two years.
Medetomidine is in the same drug class as xylazine, but it is substantially more potent, by some estimates up to 300 times, and is closely related to dexmedetomidine, a sedative used in hospital intensive care units.
One practical note for families who have been reading about xylazine: medetomidine does not appear to cause the severe skin wounds xylazine is known for. If you have been using wounds as your signal that tranq is involved, that signal no longer works.
Why This Breaks the Standard Detox Protocol
Here is the part that matters clinically, explained plainly.
Opioids like fentanyl act on opioid receptors. Buprenorphine and methadone, the medications a detox facility uses, work because they act on those same receptors. That is the entire logic of a standard opioid detox.
Xylazine and medetomidine are not opioids. They act on a completely different system, the alpha-2 adrenergic system, which regulates blood pressure, heart rate, and the body's stress response. Buprenorphine does not touch that system. Neither does methadone.
So a person coming off tranq dope has two separate physical dependencies happening at the same time. A standard detox addresses one of them. The other goes untreated.
What that looks like in practice: a patient is dosed appropriately on buprenorphine and should be stabilizing, but is still in visible crisis. If the clinical team does not understand why, the common misread is that the patient is exaggerating or drug-seeking. The patient is neither. They are in withdrawal from something the protocol never accounted for.
Why This Withdrawal Is Medically Dangerous, Not Just Miserable
Opioid withdrawal is genuinely awful. It is also rarely life-threatening on its own. Families are often told this, and it is generally true.
Alpha-2 withdrawal is a different situation. Because these drugs suppress the body's stress-response system, chronic use means the body adapts to that suppression. Take the drug away suddenly and the system rebounds hard: severe high blood pressure, racing heart rate, agitation, vomiting. That is a cardiovascular event.
Cases have been severe enough to require hospitalization and intensive care. The CDC documented a cluster of severe medetomidine withdrawal cases in Pittsburgh between October 2024 and March 2025. Public health departments in Baltimore, New York City, Philadelphia, and Chicago have issued their own advisories.
The Timing Problem Families Should Understand
That timing creates a specific trap. Someone can arrive at a facility looking manageable, get admitted, and then deteriorate on day two or three, exactly when a short detox stay is winding down or when a handoff to the next level of care is being arranged. If the facility is not anticipating that curve, the worst of it can land at the moment there is the least clinical attention on the patient.
Why Facilities Are Behind on This, and It Isn't Dishonesty
When you call a facility and ask if they can handle tranq detox, you will almost always be told yes. In most cases nobody is lying to you.
The supply changed faster than clinical protocols did. A medical director who updated the facility's approach to account for xylazine did the right thing at the time, and that update is now partially outdated. A detox nurse in a region where medetomidine has not shown up yet may not have seen a case. The answer you get on the phone reflects what that facility has historically seen, which is not necessarily what is in the drug supply your loved one has been using.
There is also a testing gap. Neither xylazine nor medetomidine appears on standard urine drug panels. A facility usually cannot confirm what it is dealing with through labs. Recognition depends on clinical judgment and current knowledge, which means a team that is not up to date may not identify what is happening even while it is happening in front of them.
Where This Is Documented, and Where It's Going
Most of the hard data so far comes from the Northeast and Midwest: Philadelphia, Pittsburgh, Baltimore, New York City, Chicago. Medetomidine was first identified in illicit samples in Maryland in 2022 and was linked to overdose and withdrawal cases in Philadelphia, Pittsburgh, and Chicago by 2024.
My read, based on how fentanyl moved through the drug supply over the last decade, is that this spreads outward the same way. Fentanyl was a regional story before it was a national one, and the gap between when the supply changed and when treatment protocols caught up was where a lot of people got hurt.
That is a prediction, not a documented fact, and I want to be clear about the difference. But it points to something practical: if you are in a region where this has not shown up much yet, that is precisely where a facility is most likely to be operating on older assumptions. It is a reason to ask more questions, not fewer.
What This Means for Level of Care
The practical takeaway is that this situation calls for medical detox with real clinical capacity, not a program that treats detox as an intake formality on the way to residential.
Specifically, the concerns worth thinking through:
Can the facility manage a cardiovascular emergency, or would they have to send your loved one out? Many standalone detox programs and most residential programs cannot handle a hypertensive crisis in house.
Does the length of stay match the withdrawal curve? If withdrawal peaks at 48 to 72 hours, a short detox stay may discharge someone directly into the worst of it.
Who owns the handoff? If detox and residential treatment are separate organizations, the transition between them is where people fall out of care entirely, and with this withdrawal timeline, that gap can land at the highest-risk moment.
Our Levels of Care article covers how facilities are supposed to determine the right level of care, and our Medical Detox by Substance guide covers what to ask about detox protocols more broadly.
Questions to Ask a Facility
- Have you treated patients with medetomidine or xylazine in their system, and how recently?
- How do you address alpha-2 withdrawal specifically, given that buprenorphine and methadone do not act on that system?
- What is your plan if my loved one's blood pressure and heart rate spike severely during withdrawal?
- Can you manage that in house, or would you transfer to a hospital?
- How long is your detox stay, and how does that line up with a withdrawal that peaks at 24 to 72 hours?
- Who coordinates the transition from detox to the next level of care, and what happens if my loved one destabilizes during that handoff?
- You cannot test for these substances on a standard panel, so how does your clinical team identify what they are dealing with?
If a facility answers these confidently and specifically, that tells you something. If the answers are vague, or if you get a general reassurance that they handle all opioid detoxes the same way, that tells you something too.
You Don't Have to Evaluate This Alone
Knowing what to ask is the first half. Knowing whether an answer is actually good is the second half, and that part is harder when you are making decisions quickly and under pressure.
If you are trying to figure out whether a facility is genuinely equipped for this, or you need help coordinating a detox and a transition into ongoing care without your loved one falling through the gap in between, that is the kind of situation I help families work through. Book a consultation here.